Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

CRB-913

Stage Phase 1Stale

Sponsor Corbus Pharmaceuticals Inc.

Sources

registry, as of 2026-10-09Stale

https://clinicaltrials.gov/study/NCT07310901

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Corbus Pharmaceuticals Inc.. Enrollment 254. Conditions Obese But Otherwise Healthy Participants. This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to eval

ClinicalTrials.gov NCT07310901 protocol and results modules

Studies

CANYON-1

Registry NCT07310901

Phase Phase 1

Status Completed

Enrollment 254

Start 2025-12-04

Primary completion 2026-08-03

Study completion 2026-08-03

Catalyst Primary completion. 2026-08-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part 1: PK Lead-in

Comparator placebo

Population Obese But Otherwise Healthy Participants

Part 2: CRB-913 low dose

Comparator placebo

Population Obese But Otherwise Healthy Participants

Part 2: CRB-913 Medium Dose

Comparator placebo

Population Obese But Otherwise Healthy Participants

Part 2: CRB-913 High Dose

Comparator placebo

Population Obese But Otherwise Healthy Participants

Part 2: Placebo

Population Obese But Otherwise Healthy Participants